Drilldown: Medicines - Pharmacopedia

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Botanical

or D2/D3/5HT1A partial agonist

or Research material

Use the filters below to narrow your results.

Other values:

None (153) · (none, never marketed) (1) · O-DSMT (1) · Vraylar (1)

5-HT2A agonist (26) · Monoamine releasing agent (9) · GABAA positive allosteric modulator (8) · CB1/CB2 agonist (7) · Dopamine/norepinephrine reuptake inhibitor (5) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Serotonin/norepinephrine/dopamine releasing agent (3) · Cathinone analogue; monoamine reuptake inhibitor (2) · Contains LSA (2) · Contains mescaline (2) · Dopamine and norepinephrine reuptake inhibitor (2) · NMDA antagonist (2) · Prodrug of GHB (2)

Other values:

None (154) · No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) · Schizophrenia (FDA-approved 2015). Acute manic or mixed episodes of bipolar I disorder. Bipolar I depression (FDA-approved 2019). Adjunctive treatment of major depressive disorder (FDA-approved Dec 2022). (1)

None (154) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1) · Schizophrenia: 1.5 mg PO daily, increase to 1.5-6 mg as tolerated. Bipolar mania: 1.5 mg, may increase to 3-6 mg. Bipolar depression: 1.5 mg daily for 14 days, then 3 mg. MDD adjunct: 1.5 mg, may increase to 3 mg. (1)

None (154) · 1.5 mg, 3 mg, 4.5 mg, 6 mg capsules (1) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1)

None (154) · 6 mg/d (psychosis/mania); 3 mg/d (depression adjunct) (1) · N/A (never approved) (1)

None (154) · intranasal; rectal and IV reported. (1) · Oral (2) · sublingual (1)

None (154) · Weeks for psychosis/mood efficacy (1) · ~20–40 min PO; faster sublingual/intranasal. (1)

None (154) · 6–10 h subjective; full pharmacologic effect considerably longer. (1) · Daily dosing; active metabolites with very long half-lives (up to 1-3 weeks) (1)

None (154) · Cariprazine ~2-4 d; major active metabolites desmethyl-cariprazine (DCAR) ~1-3 weeks → 'oral depot' effect with delayed steady-state and reduced effect of missed doses (1) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1)

None (154) · Adequate oral bioavailability (1) · Not formally characterized in humans. (1)

None (154) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) · Limited data (1)

None (155) · Rx (1)

Showing below up to 156 results in range #1 to #156.

1

2

3

4

5

7

7-Hydroxymitragynine

A

B

C

D

E

F

G

GBL

H

Harmaline

I

J

K

Kava
Kratom

L

LSH
LSZ

M

N

O

P

R

RTI-111

S

T

U

U-47700

Y

Yopo

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"